P&G Throws Weight Behind Consumer Growth After Shedding Pharma
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble faces several options - and some potential challenges - to grow its OTC portfolio using the resources gained in the sale of its prescription drug business